Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
45.77 (1y: +44%)
Market Cap 4.82 B P/E(ttm) 26.00
Enterprise Value 6.4 B P/B 1.40
OCR- NYSE (USA)
Omnicare Inc
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$45.77
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.221
OCR's Cash to Debt is ranked higher than
52% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. OCR: 0.221 )
OCR' s 10-Year Cash to Debt Range
Min: 0.05   Max: 0.29
Current: 0.22
0.05
0.29
Equity to Asset -0.136
OCR's Equity to Asset is ranked lower than
79% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.26 vs. OCR: -0.136 )
OCR' s 10-Year Equity to Asset Range
Min: -0.2   Max: 0.04
Current: -0.14
-0.2
0.04
Interest Coverage 3.3
OCR's Interest Coverage is ranked higher than
99% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. OCR: 3.3 )
OCR' s 10-Year Interest Coverage Range
Min: 1   Max: 7
Current: 3.3
1
7
F-Score: 6
Z-Score: 2.41
M-Score: -2.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 7.30
OCR's Operating margin (%) is ranked higher than
59% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.30 vs. OCR: 7.30 )
OCR' s 10-Year Operating margin (%) Range
Min: 1.3   Max: 11.1
Current: 7.3
1.3
11.1
Net-margin (%) 3.2
OCR's Net-margin (%) is ranked higher than
54% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. OCR: 3.2 )
OCR' s 10-Year Net-margin (%) Range
Min: -1.7   Max: 5.7
Current: 3.2
-1.7
5.7
ROE (%) 5.6
OCR's ROE (%) is ranked lower than
63% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.20 vs. OCR: 5.6 )
OCR' s 10-Year ROE (%) Range
Min: -2.8   Max: 12.2
Current: 5.6
-2.8
12.2
ROA (%) 2.8
OCR's ROA (%) is ranked lower than
55% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. OCR: 2.8 )
OCR' s 10-Year ROA (%) Range
Min: -1.4   Max: 6.1
Current: 2.8
-1.4
6.1
ROC (Joel Greenblatt) (%) 30.60
OCR's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 17.40 vs. OCR: 30.60 )
OCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.2   Max: 43
Current: 30.6
5.2
43
Revenue Growth (%) 1
OCR's Revenue Growth (%) is ranked lower than
52% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.50 vs. OCR: 1 )
OCR' s 10-Year Revenue Growth (%) Range
Min: -0.3   Max: 15.4
Current: 1
-0.3
15.4
EBITDA Growth (%) -0.1
OCR's EBITDA Growth (%) is ranked higher than
65% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.70 vs. OCR: -0.1 )
OCR' s 10-Year EBITDA Growth (%) Range
Min: -14.5   Max: 14.1
Current: -0.1
-14.5
14.1
EPS Growth (%) -1
OCR's EPS Growth (%) is ranked higher than
54% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. OCR: -1 )
OCR' s 10-Year EPS Growth (%) Range
Min: -18.9   Max: 38.1
Current: -1
-18.9
38.1
» OCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

OCR Guru Trades in Q2 2012

Joel Greenblatt 55,131 sh (New)
Steven Cohen 627,492 sh (+113.65%)
HOTCHKIS & WILEY 1,567,789 sh (+13.9%)
First Pacific Advisors 6,451,900 sh (+12.05%)
Steven Romick 5,760,000 sh (+10.34%)
James Barrow 4,028,725 sh (+3.62%)
Wallace Weitz 1,631,920 sh (unchged)
Jean-Marie Eveillard 2,001,000 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Chuck Royce 76,799 sh (-12.13%)
Jim Simons 539,055 sh (-41.1%)
» More
Q3 2012

OCR Guru Trades in Q3 2012

HOTCHKIS & WILEY 1,590,989 sh (+1.48%)
First Pacific Advisors 6,453,400 sh (+0.02%)
Jean-Marie Eveillard 2,001,000 sh (unchged)
Steven Romick 5,760,000 sh (unchged)
Chuck Royce 76,499 sh (-0.39%)
Wallace Weitz 1,621,920 sh (-0.61%)
James Barrow 3,968,125 sh (-1.5%)
Steven Cohen 560,946 sh (-10.61%)
Jim Simons 121,455 sh (-77.47%)
Joel Greenblatt 10,660 sh (-80.66%)
» More
Q4 2012

OCR Guru Trades in Q4 2012

Jim Simons 652,655 sh (+437.36%)
First Pacific Advisors 6,553,000 sh (+1.54%)
Steven Romick 5,846,000 sh (+1.49%)
Jean-Marie Eveillard 2,001,000 sh (unchged)
Wallace Weitz 1,621,920 sh (unchged)
Joel Greenblatt Sold Out
James Barrow 3,965,780 sh (-0.06%)
Chuck Royce 71,699 sh (-6.27%)
HOTCHKIS & WILEY 1,435,189 sh (-9.79%)
Steven Cohen 173,676 sh (-69.04%)
» More
Q1 2013

OCR Guru Trades in Q1 2013

Joel Greenblatt 122,850 sh (New)
Steven Cohen 596,776 sh (+243.61%)
Jean-Marie Eveillard 2,178,800 sh (+8.89%)
James Barrow 4,062,120 sh (+2.43%)
Steven Romick 5,846,000 sh (unchged)
First Pacific Advisors 6,538,500 sh (-0.22%)
Chuck Royce 71,099 sh (-0.84%)
HOTCHKIS & WILEY 1,413,189 sh (-1.53%)
Wallace Weitz 1,576,420 sh (-2.81%)
Jim Simons 450,500 sh (-30.97%)
» More
» Details

Insider Trades

Latest Guru Trades with OCR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 New Buy0.25%$36.1 - $40.72 $ 46.1520%122850
Joel Greenblatt 2012-12-31 Sold Out 0.02%$32.98 - $36.59 $ 46.1533%0
Joel Greenblatt 2012-09-30 Reduce -80.66%0.1%$30.68 - $35.53 $ 46.1543%10660
Joel Greenblatt 2012-06-30 New Buy0.13%$29.5 - $36.01 $ 46.1539%55131
Ray Dalio 2012-06-30 Sold Out 0.06%$29.5 - $36.01 $ 46.1539%0
Joel Greenblatt 2012-03-31 Sold Out 0.2%$32.51 - $35.56 $ 46.1545%0
Ray Dalio 2012-03-31 Add 1622.17%0.05%$32.51 - $35.56 $ 46.1545%101281
David Dreman 2011-12-31 Sold Out 0.06%$21.62 - $35.05 $ 46.1554%0
Joel Greenblatt 2011-12-31 Reduce -20.99%0.05%$21.62 - $35.05 $ 46.1554%47467
Ray Dalio 2011-12-31 New Buy$21.62 - $35.05 $ 46.1554%5881
Joel Greenblatt 2011-09-30 Add 239.78%0.18%$25.21 - $32.98 $ 46.1558%60077
Wallace Weitz 2011-06-30 Reduce -49.78%2.77%$30.42 - $32.86 $ 46.1547%2038540
Joel Greenblatt 2011-03-31 New Buy0.19%$24.59 - $30.62 $ 46.1568%21619
George Soros 2011-03-31 Sold Out $24.59 - $30.62 $ 46.1568%0
Wallace Weitz 2010-12-31 Add 7.61%0.42%$22.22 - $25.75 $ 46.1593%4742273
Jean-Marie Eveillard 2010-12-31 New Buy0.17%$22.22 - $25.75 $ 46.1593%1181300
George Soros 2010-12-31 Reduce -34.86%$22.22 - $25.75 $ 46.1593%11400
Wallace Weitz 2010-09-30 Add 21.55%0.93%$19.2 - $26.45 $ 46.15106%4406973
David Dreman 2010-09-30 Add 28.33%0.02%$19.2 - $26.45 $ 46.15106%136422
George Soros 2010-09-30 Reduce -26.47%$19.2 - $26.45 $ 46.15106%17500
Wallace Weitz 2010-06-30 Add 41.5%1.38%$23.85 - $30.38 $ 46.1572%3625535
Mario Gabelli 2010-06-30 Sold Out $23.85 - $30.38 $ 46.1572%0
Wallace Weitz 2010-03-31 Add 3.07%0.12%$24.18 - $29.29 $ 46.1574%2562260
George Soros 2010-03-31 Add 91.06%$24.18 - $29.29 $ 46.1574%23500
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 26.20
OCR's P/E(ttm) is ranked lower than
57% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 16.20 vs. OCR: 26.20 )
OCR' s 10-Year P/E(ttm) Range
Min: 10.9   Max: 79.94
Current: 26.2
10.9
79.94
P/B 1.40
OCR's P/B is ranked higher than
76% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.99 vs. OCR: 1.40 )
OCR' s 10-Year P/B Range
Min: 0.6   Max: 3.01
Current: 1.4
0.6
3.01
P/S 0.84
OCR's P/S is ranked higher than
54% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.81 vs. OCR: 0.84 )
OCR' s 10-Year P/S Range
Min: 0.33   Max: 1.43
Current: 0.84
0.33
1.43
PFCF 11.40
OCR's PFCF is ranked higher than
64% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 14.34 vs. OCR: 11.40 )
OCR' s 10-Year PFCF Range
Min: 4.79   Max: 71.06
Current: 11.4
4.79
71.06
EV-to-EBIT 14.3
OCR's EV-to-EBIT is ranked higher than
65% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 13.20 vs. OCR: 14.3 )
OCR' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 69.6
Current: 14.3
8.5
69.6
PEG 8.5
OCR's PEG is ranked lower than
66% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. OCR: 8.5 )
OCR' s 10-Year PEG Range
Min: 0.75   Max: 820
Current: 8.5
0.75
820
Shiller P/E 45.3
OCR's Shiller P/E is ranked higher than
65% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.50 vs. OCR: 45.3 )
OCR' s 10-Year Shiller P/E Range
Min: 9.15   Max: 45.5
Current: 45.3
9.15
45.5

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.06
OCR's Dividend Yield is ranked higher than
72% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.85 vs. OCR: 1.06 )
OCR' s 10-Year Dividend Yield Range
Min: 0.15   Max: 1.31
Current: 1.06
0.15
1.31
Dividend Payout 0.2804
OCR's Dividend Payout is ranked higher than
93% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.75 vs. OCR: 0.2804 )
OCR' s 10-Year Dividend Payout Range
Min: 0.04   Max: 0.24
Current: 0.28
0.04
0.24
Dividend growth (3y) 47
OCR's Dividend growth (3y) is ranked higher than
97% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: -6.00 vs. OCR: 47 )
OCR' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 47
Current: 47
0
47
Yield on cost (5-Year) 6.69
OCR's Yield on cost (5-Year) is ranked higher than
80% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. OCR: 6.69 )
OCR' s 10-Year Yield on cost (5-Year) Range
Min: 0.91   Max: 7.97
Current: 6.69
0.91
7.97
Share Buyback Rate 1
OCR's Share Buyback Rate is ranked higher than
87% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: -0.60 vs. OCR: 1 )
OCR' s 10-Year Share Buyback Rate Range
Min: 1   Max: -4.7
Current: 1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 6
OCR's Price/Net Current Asset Value is ranked higher than
56% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 6.55 vs. OCR: 6 )
OCR' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 6.2
Current: 6
2.2
6.2
Price/DCF (Projected) 0.7
OCR's Price/DCF (Projected) is ranked higher than
76% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.80 vs. OCR: 0.7 )
OCR' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 2.8
Current: 0.7
0.5
2.8
Price/Median PS Value 1.1
OCR's Price/Median PS Value is ranked higher than
64% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.90 vs. OCR: 1.1 )
OCR' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.6
Current: 1.1
0.6
1.6
Earnings Yield (Greenblatt) 7.00
OCR's Earnings Yield (Greenblatt) is ranked higher than
67% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. OCR: 7.00 )
OCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 11.8
Current: 7
1.4
11.8
Forward Rate of Return (Yacktman) 8.89
OCR's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.99 vs. OCR: 8.89 )
OCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.1   Max: 19.1
Current: 8.89
-3.1
19.1

Business Description

Omnicare Inc was formed in 1981. Omnicare is a healthcare services company that specializes in the management of complex pharmaceutical care. It operates in two primary businesses, Long-Term Care Group ('LTC') and Specialty Care Group ('SCG'). Through LTC, Omnicare is the provider of pharmaceuticals and related pharmacy and ancillary services to long-term care facilities as well as chronic care facilities and other settings. SCG provides commercialization services for the biopharmaceutical industry in addition to end-of-life pharmaceutical care management for hospice care agencies. With respect to its clinical services, the Company provides pharmacy consulting, including monthly patient drug therapy evaluations, assist in compliance with state and federal regulations and provide proprietary clinical and health management programs. LTC also provides a suite of technology solutions based largely on its Omniview web-based platform that is intended to improve the efficiency of its customers' operations through such tools as the electronic ordering of prescription refills, proof-of-delivery tracking, and real-time validation of Medicare Part D coverage, among others. LTC also provides a number of other products and services, including intravenous medications and nutrition products (infusion therapy products and services), respiratory therapy services, medical supplies and equipment (including billing the Medicare Part B program for eligible patients) and clinical care planning. The Company also provides pharmaceutical case management services for retirees, employees and dependents who have drug benefits under corporate-sponsored healthcare programs. SCG touches a broad spectrum of the healthcare continuum, serving the needs of biopharmaceutical manufacturers, physicians, nurses, caregivers and patients. Its services are largely centered on the specialty pharmaceutical market. These services are based on five platforms: brand support services, third party logistics, patient assistance programs, specialty pharmacy and disease management for end-of-life care. Its brand support services, third party logistics and patient assistance programs are integrated, fee-for-service platforms which focus on helping the drug manufacturer to market, to distribute and obtain reimbursement for their products. In its specialty pharmacy platform, the Commpany provides dispensing of specialized pharmaceuticals that are high cost, have complex reimbursement and supply chain challenges, have limited patient populations and are not available through normal retail channels. These specialized drugs deal primarily with specific categories of drugs and disease states, such as rheumatoid arthritis, multiple sclerosis, oncology and growth hormones. LTC's customers consist of skilled nursing facilities, assisted living facilities, independent living communities, hospitals, correctional facilities, and other healthcare service providers. The Company's largest competi
Company Website
SEC Reports
Industry: Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF
» More Articles for OCR

Headlines

Articles On GuruFocus.com
Steven Romick on WealthTrack Oct 20 2012 
Steven Romick on Stock Picks, Bonds and Farmland Oct 08 2012 
The Best Stocks With Dividend Growth From Last Week (September 10 – September 16, 2012) Sep 16 2012 
Weekly CEO Buys Highlight: SYMC, TDY, PNK, FNFG, OCR Aug 04 2012 
First Pacific Advisors Buys Lowes Cos., Aon Corp., Cit Group Inc., Sells Abbott Laboratories, Amgen Nov 19 2011 
Weitz Partners Value Fund Commentary: CVS, TGT, BRK.A, BRK.B Nov 11 2011 
FPA Crescent Fund Q3 Portfolio Update Oct 14 2011 
Wallace Weitz’s Diverse Portfolio Sep 20 2011 
Daily Dividend Report: HNZ, OCR, SEIC, FPTB, EDE, FISI May 26 2011 
First Pacific Advisors Buys CVS, MSFT, WMT, AON, PFE, OCR, TOT, Sells MCY, PHG, HNT, CVX, GKSR, LOW Feb 16 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial